Endpoints and clinical trial design for nonalcoholic steatohepatitis
Arun J. Sanyal(Virginia Commonwealth University), Arthur J. McCullough(Cleveland Clinic), Elizabeth M. Brunt(Washington University in St. Louis), Vlad Ratziu(Inserm), Naga Chalasani(Indiana University – Purdue University Indianapolis), David E. Kleiner(National Institutes of Health), Kris V. Kowdley(Liver Institute Northwest), Joel E. Lavine(Columbia University)
Cited by 757
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k